Efficacy of Levetiracetam in early post-stroke seizures
- Conditions
- Patients with a first seizure after an ischemic cerebral infarction.
- Registration Number
- EUCTR2005-002445-40-DE
- Lead Sponsor
- eurologische Klinik Bad Neustadt
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 20
Age > 18 years
First seizure according to the actual classification of the international league against epilepsy (ILAE 1989)
Seizure between 48 hours and 14 days after stroke
Clinical and computertompgraphic proof of hemispherical infarction
Written informed consent
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Patients with brain stem or cerebellar infarction
Patients with progredient neurological, degenerative, malignant or other diseases which interfere with the study
Patients with primary cerebral hemorrhage
Patients with diseases judged as clinically relevant by the physician (cardiovascular, hepatic, renal, endocrinological, psychiatric diseases) and who interfere with the study (life expectancy below 5 years)
Patients with anamnestic hints for epileptioc seizures
Patient with migraine
Patients with known hypersensitivity against Levetiracetam or Piracetam
Participation in another clinbical trial in within the last 30 days
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method